Amneal Pharmaceuticals (AMRX) Q4 Earnings Top Estimates

Core Viewpoint - Amneal Pharmaceuticals reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, and showing an increase from $0.12 per share a year ago, resulting in an earnings surprise of +18.85% [1] Financial Performance - The company achieved revenues of $814.32 million for the quarter ended December 2025, which was slightly below the Zacks Consensus Estimate by 0.19%, but an increase from $730.52 million year-over-year [2] - Over the last four quarters, Amneal has surpassed consensus EPS estimates four times, but has only topped consensus revenue estimates once [2] Stock Performance - Amneal shares have increased approximately 15% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.9% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $753.87 million, and for the current fiscal year, it is $0.96 on revenues of $3.21 billion [7] - The estimate revisions trend for Amneal was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Amneal belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, suggesting that the overall industry outlook may impact stock performance [8]